Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211802 · ClinicalTrials.gov registry record · Phase 3
CKM For Safe Use of SGLT2i in Type 1 Diabetes
A Phase 3 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT07211802: Clinical Trial Phase 3 study, sponsored by University of California, San Diego.
NCT07211802 is a Phase 3 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 52 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07211802, a Phase 3 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
Primary Outcome
Beta hydroxybutyrate (BHB) time \> 0.6 millimole per liter (mmol/L) as measured by the DGK during the 200mg dosing period in the MDI vs. HCL groups.
Interventions
- DRUG Sotagliflozin Low Dose
- DRUG Sotagliflozin High Dose
- DEVICE Dual Continuous Glucose and Ketone Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
What is known before NCT07211802 opens enrollment
NCT07211802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Sotagliflozin Low Dose is the first listed.
NCT07211802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07211802 about?
NCT07211802 is a clinical study titled "CKM For Safe Use of SGLT2i in Type 1 Diabetes". This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
What is the current status of trial NCT07211802?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2026-07-01. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07211802?
The interventions under investigation include: Sotagliflozin Low Dose (DRUG), Sotagliflozin High Dose (DRUG), Dual Continuous Glucose and Ketone Monitor (DEVICE).
Who is sponsoring clinical trial NCT07211802?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07211802's enrollment target sits among peer trials
52 1841st of 2000 higher than 159 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI